Hints and tips:
...“No one’s saying they shouldn’t make money,” Jones-Monteiro said. “It’s just the extent of it.”...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Write to the FintechFT team at imani.moise@ft.com and sid.v@ft.com....
...after jabs developed by Pfizer, AstraZeneca and Sinovac....
...J&J is following many other large pharmaceutical companies that have shed their consumer divisions, including GSK and Pfizer, which formed a joint venture from their consumer health units that they plan...
...A year later GSK and Pfizer formed a joint venture from their consumer products divisions, which they plan to spin off next year....
...This is not just a recent phenomenon: Adam quotes Mark Jones, former director of London’s V&A, on Richard Wallace (1818-90), founder of the Wallace Collection, who “was an outsider, because of being illegitimate...
...Trust in different vaccine brands also varied, with the Pfizer/BioNTech vaccine being the most trusted across all age groups in nine of the 15 countries....
...– Tesla v NIO. – Former Alphavillain v Blanchard. – Denmark’s children's TV show on the hardships of being well hung. – Covid demands fast decisions....
...The three countries are in talks with Pfizer and Moderna about the factories....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...Ian Jones, a professor of virology at the University of Reading, said the study added to existing evidence that showed bone marrow cells that make protective antibodies against Covid-19 could be found in...
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Ian Jones, professor of virology at the University of Reading, said the BioNTech vaccine had always looked like “the most bang-per-buck”....
...Another Frenchman, Charles Tellier, developed refrigerated ships in the 1860s, though it was seven decades before Frederick McKinley Jones created cooling for trucks that could cope with the vibration of...
...This doesn’t mean we are in the midst of a V-shaped recovery, however....
...Merck was the best performer in the Dow Jones Industrial Average last year, up 35.8 per cent, helped by investors’ excitement at the sales of Keytruda....
...The drugmaker Merck put in the best performance by a member of the Dow Jones Industrial Average, as healthcare stocks emerged as the winning sector of the market in 2018....
...The Dow Jones Industrial Average ended the day up 0.28 per cent to 22,118.8....
...The Dow Jones Industrial Average ended the day up 0.19 per cent to 22,412.6, lifted by gains for burger chain McDonald’s, pharmaceutical giant Pfizer and aerospace manufacturer Boeing, while Apple weighed...
...Pfizer dropped 1.2 per cent, Merck shed 2 per cent while Eli Lilly and Bristol-Myers Squibb both lost 1 per cent....
International Edition